17 results
Thumbnail

D3.84 - Delayed hypersensitivity to hydroxychloroquine with positive patch test

Thumbnail

D3.85 - Evaluation of a new Multiplex Allergen Test Kit for the simultaneous detection of allergen specific IgE

Thumbnail

D3.87 - Assessing the agreement between skin prick test and specific-IgE for ten common food allergens in infants

Thumbnail

D3.89 - Unexpected Culprit: The Role of Acrylates in Recurrent Anaphylaxis and Antibiotic Hypersensitivity

Thumbnail

D3.91 - Safety of Skin Prick Tests: more than 30 years of spontaneous data from real practice

Thumbnail

D3.94 - Optimizing the Diagnosis and Treatment of Psoriasis Associated with Streptococcal Infection

Thumbnail

D3.88 - 5-Year Metal Patch Testing Analysis of a Portuguese Immunology an Allergology Center: Allergen relevance and Cluster identification

Thumbnail

D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab

Thumbnail

D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab

Thumbnail

D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis

Thumbnail

D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic

Thumbnail

D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates

Thumbnail

D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab

Thumbnail

D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results

Thumbnail

D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years

Thumbnail

D1.369 - Characteristics of patients with severe asthma undergoing biological treatment at a reference center

Thumbnail

D1.371 - Dupilumab for the treatment of refractory severe chronic spontaneous urticaria